专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

52. 发明授权

EP2866839B1 FUNCTIONALIZED LIPOSOMES USEFUL FOR THE DELIVERY OF BIOACTIVE COMPOUNDS 有权
公开(公告)号：EP2866839B1
公开(公告)日：2018-08-15
申请号：EP13732179.0
申请日：2013-06-28
申请人： Consejo Superior De Investigaciones Científicas (CSIC) , Fundació Parc Científic de Barcelona , CIBER Centro de Investigación Biomédica en Red , Fundació Institut de Recerca Biomèdica (IRB Barcelona) , Universitat de Barcelona , Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca , Universitat Autònoma de Barcelona
发明人： VENTOSA RULL, Leonor , VECIANA MIRÓ, Jaume , CABRERA PUIG, Ingrid , ELIZONDO SAEZ DE VICUÑA, Elisa , MELGAREJO DIAZ, Marta , ROYO EXPÓSITO, Miriam , ALBERICIO PALOMERA, Fernando , PULIDO MARTINEZ, Daniel , SALA VERGÉS, Santiago , CORCHERO NIETO, Jose Luis , SCHWARTZ NAVARRO, Simón , ABASOLO OLAORTUA, Ibane , VILLAVERDE CORRALES, Antonio Pedro
IPC分类号： A61K47/50
CPC分类号： A61K47/646 , A61K38/47 , A61K47/54 , A61K47/554 , A61K47/60 , A61K47/64 , A61K47/6435 , A61K47/6911 , A61K47/6915 , C12Y302/01022 , Y10T428/2982
摘要： The invention relates to conjugates in which a sterol is functionalized by an ether bond with a water-soluble polymer to which a guiding ligand is bound. These conjugates improve the physico-chemical and delivery properties of their carrying vesicles, making these more stable, homogeneous and effective. A method for their preparation, a pharmaceutical composition containing said liposomes, and their therapeutic use are described as well.

53. 发明公开

EP3335730A1 COMPOUNDS FOR TREATING X-LINKED ADRENOLEUKODYSTROPHY 审中-公开
公开(公告)号：EP3335730A1
公开(公告)日：2018-06-20
申请号：EP16382602.7
申请日：2016-12-15
申请人： Fundació Institut de Recerca Biomédica de Bellvitge (IDIBELL) , Centro de Investigación Biomédica en Red (CIBER)
发明人： PUJOL ONOFRE, Aurora
IPC分类号： A61K45/06 , A61K31/436 , A61K31/137 , A61K31/19 , A61K31/198 , A61K31/355 , A61K31/385 , A61K31/397 , A61K31/4439 , A61K31/575 , A61P3/00 , A61P25/00 , A61P43/00
CPC分类号： A61K31/575 , A61K31/137 , A61K31/19 , A61K31/198 , A61K31/355 , A61K31/385 , A61K31/397 , A61K31/436 , A61K31/4439 , A61K45/06 , A61K2300/00
摘要： The invention relates to a compound of formula (I)

as described in the invention, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, or a mixture thereof for use in the prevention and/or treatment of a disease caused by loss of function of ABCD1 gene, a disease caused by accumulation of very long fatty acids in organs and plasma or of a peroxisomal disorder. The invention also relates to combinations comprising (i) a compound of formula (I) and ii) an antioxidant, an activator of mitochondria biogenesis, an antiinflammatory compound, an activator of autophagy, a peroxisomal biogenesis activator or a mixture thereof, and the medical use of said combinations.

54. 发明授权

EP3017068B1 PRIMERS AND METHODS FOR DETECTING HUMAN HEPATITIS C VIRUS (HCV) VARIANTS IN AN ISOLATED SAMPLE 有权转让
标题翻译：用于检测分离的样品中的人类丙型肝炎病毒（HCV）变体的引物和方法
公开(公告)号：EP3017068B1
公开(公告)日：2018-04-18
申请号：EP14736385.7
申请日：2014-07-04
申请人： Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca , CIBER (Centro de Investigación Biomédica en Red) , Roche Diagnòstics S.L.
发明人： QUER, Josep , RODRÍGUEZ, Francisco , GREGORI, Josep
IPC分类号： C12Q1/70
CPC分类号： C12Q1/707 , C12Q2600/112 , C12Q2600/156 , C12Q2600/16
摘要： The invention relates to an in vitro method for determining in an isolated sample of a subject the presence of one or more Human Hepatitis C Virus (HCV) sequence variants comprising reverse transcription and amplifying HCV RNAs molecules using specific sets of primers allowing the amplification of the HCV regions named 5'-UTR-Core and NS5B. The method includes an step for purifying the amplified regions and a sequencing step of the amplified fragments. The invention also includes specific oligonucleotides than are used as primers in the method, as well as kits including one or more of these oligonucleotides as sets of primers.

55. 发明公开

EP3239303A1 IN VITRO METHOD FOR IDENTIFYING PANCREATIC CANCER OR INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM OF THE PANCREAS 审中-公开
标题翻译：用于鉴定胰腺癌或胰腺内浸润性毛细血管内皮细胞的体外方法
公开(公告)号：EP3239303A1
公开(公告)日：2017-11-01
申请号：EP16382182.0
申请日：2016-04-26
申请人： Advanced Marker Discovery, S.L. , Centro de Investigación Biomédica en Red , Hospital Clínic de Barcelona
发明人： GIRONELLA COS, Meritxel , CASTELLS GARANGOU, Antoni
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/158 , C12Q2600/178
摘要： The present invention refers to an i n vitro method for screening for subjects at risk of developing pancreatic cancer or intraductal papillary mucinous neoplasm of the pancreas (IPMN) comprising: (a) measuring the expression pattern or level of at least hsa-miR-33a*, or of at least hsa-miR-320a, or of at least hsa-let-7e, or of at least hsa-let-7f, or of at least hsa-miR-1257, or of at least hsa-miR-1304, or of at least hsa-miR-151b, or of at least hsa-miR-3120-3p, or of at least hsa-miR-3133, or of at least hsa-miR-3714, or of at least hsa-miR-4468, or of at least hsa-miR-4639-5p, or of at least hsa-miR-4713-5p, or of at least hsa-miR-4714-5p, or of at least hsa-miR-4770, or of at least hsa-miR-548d-3p, or of at least hsa-miR-761, obtained from an isolated biological sample of the subjects to be screened; and (b) comparing said expression pattern or level of at least hsa-miR-33a*, or of at least hsa-miR-320a, or of at least hsa-let-7e, or of at least hsa-let-7f, or of at least hsa-miR-1257, or of at least hsa-miR-1304, or of at least hsa-miR-151b, or of at least hsa-miR-3120-3p, or of at least hsa-miR-3133, or of at least hsa-miR-3714, or of at least hsa-miR-4468, or of at least hsa-miR-4639-5p, or of at least hsa-miR-4713-5p, or of at least hsa-miR-4714-5p, or of at least hsa-miR-4770, or of at least hsa-miR-548d-3p, or of at least hsa-miR-761, of the subjects to be screened with an already established expression pattern or level, wherein overexpression of at least any of the above mentioned miRNAs is indicative of pancreatic cancer or intraductal papillary mucinous neoplasm of the pancreas (IPMN).
摘要翻译：本发明涉及用于筛选具有胰腺癌或胰腺导管内乳头状粘液性肿瘤（IPMN）风险的受试者的体外方法，其包括：（a）测量至少hsa-miR-33a *的表达模式或水平，，或至少hsa-miR-320a或至少hsa-let-7e或至少hsa-let-7f或至少hsa-miR-1257或至少hsa-miR-1304 ，或至少hsa-miR-151b或至少hsa-miR-3120-3p，或至少hsa-miR-3133，或至少hsa-miR-3714，或至少hsa-miR 或至少hsa-miR-4639-5p，或至少hsa-miR-4713-5p，或至少hsa-miR-4714-5p，或至少hsa-miR-4770或至少hsa-miR-548d-3p或至少hsa-miR-761的至少hsa-miR-761，其从筛选的受试者的分离的生物学样品获得; 和（b）比较至少hsa-miR-33a *或至少hsa-miR-320a或至少hsa-let-7e或至少hsa-let-7f的所述表达模式或水平，或至少hsa-miR-1257或至少hsa-miR-1304或至少hsa-miR-151b或至少hsa-miR-3120-3p或至少hsa-miR- 3133或至少hsa-miR-3714，或至少hsa-miR-4468，或至少hsa-miR-4639-5p，或至少hsa-miR-4713-5p或至少hsa-miR-4713-5p hsa-miR-4714-5p或至少hsa-miR-4770或至少hsa-miR-548d-3p或至少hsa-miR-761的待筛选对象表达模式或水平，其中至少任何上述miRNA的过度表达指示胰腺的胰腺癌或导管内乳头状粘液瘤（IPMN）。

57. 发明授权

EP2603604B1 METHOD AND KIT FOR THE DIAGNOSIS AND/OR PROGNOSIS OF TOLERANCE IN LIVER TRANSPLANTATION 有权
标题翻译：用于肝脏移植中的耐受性诊断和/或预测的方法和试剂盒
公开(公告)号：EP2603604B1
公开(公告)日：2017-07-19
申请号：EP11710147.7
申请日：2011-03-02
申请人： Hospital Clínic de Barcelona , Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD)
发明人： SÁNCHEZ FUEYO, Alberto , LOZANO SALVATELLA, Juan José , MARTÍNEZ LLORDELLA, Marc , RIMOLA CASTELLA, Antoni , BOHNE, Felix
IPC分类号： C12Q1/68
CPC分类号： G01N33/84 , C12N15/1072 , C12Q1/6881 , C12Q2600/158 , G01N33/6872 , G01N33/74

58. 发明公开

EP3095877A1 METHODS AND MEANS FOR MANAGING EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL)-PRODUCING ENTEROBACTERIACEAE COLONIZATION 审中-公开
标题翻译：的方法和手段用于管理的β-内酰胺酶的产生与扩展范围肠杆菌科细菌定植
公开(公告)号：EP3095877A1
公开(公告)日：2016-11-23
申请号：EP15305758.3
申请日：2015-05-20
申请人： Universitat de València , Fundación para el Fomento de la Investigación Sanitaria y Biomedica de la comunitat Valenciana , Centro de Investigación Biomédica en Red , Université Paris Diderot - Paris 7 , ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
发明人： MOYA, Andrés , LATORRE, Amparo , GOSALBES, Maria José , VAZQUEZ CASTELLANOS, Jorge F. , ANDREMONT, Antoine , RUPPE, Etienne , WOERTHER, Paul Louis , ANGEBAULT, Cécile , DJOSSOU, Félix
IPC分类号： C12Q1/68
CPC分类号： C12Q1/689 , C12Q2600/118
摘要： The present invention relates to the field of the management of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae colonization. In particular, the present invention relates to methods for assessing the risk to develop intestinal carriage of ESBL-producing Enterobacteriaceae (E-ESBL) or for prognosing intestinal carriage of E-ESBL. More specifically, the invention relates to methods comprising a step of determining the abundance of at least one bacterium selected from the list consisting of bacteria from the genus Desulfovibrio, Oscillospira, Parabacteroides, Coprococcus and Prevotella in the gut microbiota of a subject.
A further object of this invention is to provide a new composition, for mucosal administration, comprising at least one bacterium selected from the list consisting of bacteria from the genus Desulfovibrio, Oscillospira, Parabacteroides, and Coprococcus. More particularly, this invention relates to such compositions for use in the prevention or treatment of intestinal carriage of E-ESBL in a subject in need thereof.
摘要翻译：本发明涉及广谱β-内酰胺酶（ESBL）产生肠杆菌定植的管理领域。特别地，本发明涉及一种用于assesing风险发展产生ESBL的肠杆菌科细菌（E-ESBL）的肠运输或用于预后E-ESBL的肠运输方法。更具体地，本发明涉及包含确定性采矿的步骤的丰度从列表由来自受试者中的微生物群井属脱硫，Oscillospira，Parabacteroides，Coprococcus和普氏菌的细菌中选择的至少一种细菌的方法。本发明的另一目的是提供一种新的组合物，用于粘膜给药，包括：从所述列表中由来自脱硫菌属，Oscillospira，Parabacteroides，和Coprococcus细菌中的至少一种细菌。更具体地说，本发明涉及的组合物搜索用于在需要其的受试者中预防或治疗E-ESBL的肠运输的使用。

60. 发明公开

EP2997977A1 Specific mtor inhibitors in the treatment of x-linked adrenoleukodystrophy 审中-公开
标题翻译： Spezifische MTOR-Inhibitoren zur Behandlung von X-verbundener Adrenoleukodystrophie
公开(公告)号：EP2997977A1
公开(公告)日：2016-03-23
申请号：EP14382353.2
申请日：2014-09-19
申请人： Fundación de la Comunidad Valenciana Centro de Investigación Principe Felipe , Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) , Centro de Investigación Biomédica en Red (CIBER)
发明人： Pujol Onofre, Aurora , Knecht Roberto, Erwin
IPC分类号： A61K45/06 , A61K31/436 , A61K31/05 , A61K31/132 , A61K31/138 , A61K31/194 , A61K31/277 , A61K31/341 , A61K31/343 , A61K31/451 , A61K31/506 , A61K31/5415
CPC分类号： A61K31/05 , A61K31/132 , A61K31/138 , A61K31/194 , A61K31/277 , A61K31/341 , A61K31/343 , A61K31/436 , A61K31/451 , A61K31/506 , A61K31/5415 , A61K45/06 , A61K2300/00 , C12Q1/6841 , C12Q1/686
摘要： The invention relates to novel uses of specific mTOR inhibitors as a medicament, in particular for the treatment of X-linked adrenoleukodystrophy (X-ALD). The invention also relates to a method for identifying a compound potentially useful for the treatment and/or prevention of X-ALD.
摘要翻译：本发明涉及特异性mTOR抑制剂作为药物的新用途，特别是用于治疗X连锁肾上腺脑白质营养不良（X-ALD）。本发明还涉及用于鉴定可用于治疗和/或预防X-ALD的化合物的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式